Linaclotide

Approved human use · product-specific labels.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

Linaclotide is an oral peptide that activates guanylate cyclase-C on the intestinal surface, increasing fluid secretion and helping stool move. It treats defined constipation disorders; the eligible age group depends on the diagnosis and current product label. [1]

02 Potential benefits

Increases intestinal fluid secretion and transit. Can improve constipation and abdominal pain in labeled disorders. [1]

03 Evidence & its limits

Diarrhea can be severe. The label contraindicates use in children younger than two because of serious dehydration risk, and in known or suspected mechanical gastrointestinal obstruction. Approval for one constipation diagnosis does not automatically cover another. [1]

04 Risks & unknowns

Diarrhea can be severe. Important pediatric contraindications and warnings apply. [1]

05 Status & scope

Approved human use · product-specific labels. Read the full record for product, formulation and indication-specific status; a biological role or measured response is not a treatment approval. [1]

06 The question to ask

Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates
[2] FDA Drugs@FDA database
[3] MedlinePlus: medication-specific uses and precautions
[4] LINZESS prescribing information

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.